Special Article
Cumulative Meta-Analysis of Therapeutic Trials for Myocardial Infarction
N Engl J Med 1992; 327:248-254July 23, 1992
- Abstract
- Abstract
Background.
The large volume of published randomized, controlled trials has led to a need for meta-analyses to track therapeutic advances. Performing a new meta-analysis whenever the results of a new trial of a particular therapy are published permits the study of trends in efficacy and makes it possible to determine when a new treatment appears to be significantly effective or deleterious. We describe the use of such a procedure, cumulative meta-analysis, to assess therapeutic trials among patients with myocardial infarction.
Methods.
We performed cumulative meta-analyses of clinical trials that evaluated 15 treatments and preventive measures for acute myocardial infarction.
Results.
An example of this method is its application to the use of intravenous streptokinase as thrombolytic therapy for acute infarction. Thirty-three trials evaluating this therapy were performed between 1959 and 1988. We found that a consistent, statistically significant reduction in total mortality (odds ratio, 0.74; 95 percent confidence interval, 0.59 to 0.92) was achieved in 1973, after only eight trials involving 2432 patients had been completed. The results of the 25 subsequent trials, which enrolled an additional 34,542 patients through 1988, had little or no effect on the odds ratio establishing efficacy, but simply narrowed the 95 percent confidence interval. In particular, two very large trials, the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico trial in 1986 (11,712 patients) and the Second International Study of Infarct Survival trial in 1988 (17,187 patients) did not modify the already established evidence of efficacy. We used a similar approach to study the accumulating evidence of efficacy (or lack of efficacy) of 14 other therapies and preventive measures for myocardial infarction.
Conclusions.
Cumulative meta-analysis of therapeutic trials facilitates the determination of clinical efficacy and harm and may be helpful in tracking trials, planning future trials, and making clinical recommendations for therapy. (N Engl J Med 1992;327:248–54.)
Media in This Article
Figure 1
Conventional and Cumulative Meta-Analyses of 33 Trials of Intravenous Streptokinase for Acute Myocardial Infarction.Figure 2
Cumulative Meta-Analyses of 60 Trials of Intravenous Thrombolytic Agents for Myocardial Infarction by the MantelHaenszel Fixed-Effects Method and DerSimonian and Laird Random-Effects Method.Article Activity
- Article
META-ANALYSIS of randomized, controlled trials is an increasingly important method in clinical research. Its growing importance is a natural outgrowth of the abundance of trials published each year and the small size of many trials that take varied approaches to the same problems, making definitive conclusions from any one trial rare. Defined as the quantitative synthesis of data from multiple clinical experiences, meta-analysis has matured as a scientific discipline, with well-described standards and methods.1 2 3 4
Because trials of the same treatments in approximately the same types of patients form a continuum of clinical experience, clinical investigators need a fluid approach to the ever-expanding data. We have developed techniques for routinely conducting cumulative meta-analyses (defined as the performance of an updated meta-analysis every time a new trial appears) and for evaluating the results as a continuum. These techniques make it possible to study trends in good and bad effects and to pinpoint the first time a difference in outcome between treatment and control groups becomes statistically significant at a chosen level. Searching and monitoring the clinical literature and performing cumulative meta-analyses can thus supply practitioners and policy makers with up-to-date information on emerging and established advances.
To illustrate this approach to the evaluation of therapies we have selected the treatment of acute myocardial infarction and the prevention or postponement of death after discharge from the hospital after an infarction as apt models; the end point of death from any cause is both reliable and available in almost all reports. In addition, the literature provides a large number of trials that can be combined. Finally, we have evidence that the clinical experts who write review articles and textbook chapters have often not mentioned agents with proved efficacy in reducing mortality, such as thrombolytic agents and intravenous vasodilators.5 Our retrospective approach to the treatment of acute infarction and the secondary prevention of death after infarction reveals lifesaving conclusions that could have been drawn earlier and at the same time pinpoints problems that will have to be dealt with in the future, as cumulative meta-analysis is applied more widely.
Methods
The techniques of meta-analysis of randomized, controlled trials have been well described.1 2 3 4 Traditionally, the individual trials, grouped according to the class of treatment, the end point of interest, or both, are presented in order of publication or in descending order of quality. The pooled differences between treatment and control groups are then presented as a summation of the results of the individual trials, of necessity at some arbitrary point in time after the literature search has been completed. For this discussion we focus on investigations with outcomes expressed as counts in two-by-two tables, as numbers of successes and failures in the treatment and control groups.
Two statistical models have been employed in our meta-analyses. The fixed-effects model described by Mantel and Haenszel6 assumes identical treatment effects in the studies (homogeneity of the true treatment effect), and the variances around each mean effect depend primarily on the size of each study. The random-effects model of DerSimonian and Laird7 includes between-study differences in treatment effects in the calculation of the variances, leading to wider confidence intervals when a given level of heterogeneity in treatment effect is observed.8 The MantelHaenszel results are usually reported as an odds ratio with variances calculated either by the procedure of Peto as described by Yusuf et al.1 and Collins et al.9 or by the method of Robins, Greenland, and Breslow.10 The DerSimonian and Laird results have traditionally been reported as absolute percentage differences, with confidence intervals, but they can be reported as odds ratios, as in Figure 2Figure 2
Cumulative Meta-Analyses of 60 Trials of Intravenous Thrombolytic Agents for Myocardial Infarction by the MantelHaenszel Fixed-Effects Method and DerSimonian and Laird Random-Effects Method..Although we have used several available methods in our routine analyses, we have not found important differences in over 45 meta-analyses,11 except for the anticipated wider confidence intervals of the DerSimonian and Laird method when heterogeneity in treatment effect is observed.8 We prefer the two-method approach; differences in the confidence intervals determined by each method occur only when there is heterogeneity.8 A choice can then be made between the more and the less conservative approach.
We employed the principles discussed above in cumulative meta-analysis by updating the pooled estimate of the treatment effect each time the results of a new trial were published for each of the treatments for myocardial infarction that we were evaluating. We started our literature search for meta-analyses of randomized, controlled trials of the treatment of myocardial infarction with a recent review by Yusuf et al.,12 assembled all the additional published meta-analyses of treatment and secondary prevention, and added the results of trials reported since the last meta-analyses were submitted for publication. We also searched MEDLINE and the references of published papers for randomized, controlled trials that might not have appeared in the published meta-analyses. Some of the meta-analyses included trials of different routes of administration and different drugs of the same class (e.g., the beta-blockers). Because our principal interest was the overall treatment effect of a particular therapeutic intervention, and because there were no significant differences in mortality among the various routes of administration or individual drugs within a class, we pooled all the studies of treatments within a given drug class. Although total mortality was our preferred end point, in the rare instances in which the original paper presented only mortality from cardiovascular causes we used that figure. Although most of the data on mortality were confined to the period of hospitalization, a few studies gave data only in terms of weeks or months after infarction. For the data on short-term treatment we included mortality up to a limit of three months, because of the likelihood that any deaths up to that time were directly related to the initial infarction and its treatment. When a study reported on more than one time period, we used the one closest to the time of hospitalization. For the studies of secondary prevention we included the duration described by the authors, relying on an important characteristic of meta-analysis — the fact that differences between treatment and control groups are determined before pooling, so that each study has internal controls. In presenting the significance of the results we used only two-sided P values.
We selected the treatments to include on the basis of the availability of data. For each treatment at least one meta-analysis had been published, and we then added trials published since the original meta-analysis. Eight treatments for acute myocardial infarction have been analyzed in published meta-analyses: intravenous thrombolytic drugs,13 14 15 16 17 18 19 20 21 22 intravenous vasodilators (nitroglycerin and nitroprusside),23 intravenous or oral beta-blockers,1 , 24 25 26 anticoagulants,27 antiplatelet drugs,28 lidocaine prophylaxis against primary ventricular fibrillation,29 30 31 calcium-channel blockers,32 and intravenous magnesium salts.33
The seven methods for delaying death after discharge were oral beta-blockers,1 , 24 , 34 35 36 37 38 39 anticoagulants,40 41 42 antiplatelet drugs,43 44 45 46 calcium-channel blockers,32 cholesterol-lowering treatments,47 48 49 rehabilitation exercise regimens,50 , 51 and Class I antiarrhythmic drugs.52
We obtained all but two of the original published papers that were the basis of these meta-analyses and confirmed that they were randomized, controlled trials and that their end points — death within the stated periods — could be pooled. For data published in the two papers we could not obtain and data published only in the meta-analyses, we relied on the accuracy of the authors of the meta-analyses. In pooling the results of the trials we assumed that a reasonable effort had been made by the original investigators to include all patients who presented with acute myocardial infarction unless the patients had any of the then accepted contraindications to the therapy under investigation. In the absence of established subgroup responses to given agents we included trials with various criteria for acceptance and assumed that patients omitted in the absence of any other contraindications (such as those over 70 years old or living in remote areas) would not have changed the results had they been included.
Results
The data on 33 trials that compared intravenous streptokinase with a placebo or no therapy in patients who had been hospitalized for acute myocardial infarction are presented as traditional and cumulative meta-analyses in Figure 1Figure 1
Conventional and Cumulative Meta-Analyses of 33 Trials of Intravenous Streptokinase for Acute Myocardial Infarction.. In the traditional analysis the effect of treatment on total mortality for each study is presented as an odds ratio and 95 percent confidence interval, and the pooled estimate of the treatment effect with its confidence interval is presented at the bottom. Although the effect of treatment on mortality favored the active drug in 25 of the 33 trials, in only 6 was statistical significance achieved. The pooled estimate of the treatment effect, however, is significant.The same data are also presented in Figure 1 as if a new meta-analysis had been performed each time the results of a new trial were reported. The years during which the treatment effect became statistically significant by the MantelHaenszel procedure were 1971 for a two-sided P value of <0.05 (exact P = 0.023), 1973 for a P value of <0.01 (odds ratio, 0.74; 95 percent confidence interval, 0.59 to 0.92; P = 0.007), and 1977 for a P value of <0.001. With this technique it can be seen that the very large trials — the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)53 and the Second International Study of Infarct Survival (ISIS-2)28 (without the aspirin group) — did not change the already established evidence of efficacy; published in 1986 and 1988, respectively, they narrowed the confidence intervals slightly and increased the already impressive statistical significance of the overall treatment effect. The cumulative method indicates that intravenous streptokinase could have been shown to be lifesaving almost 20 years ago, long before its submission to and approval by the Food and Drug Administration and its general adoption in practice. We have not included intracoronary streptokinase or the newer intravenous thrombolytic drugs in the data shown in Figure 1 because their effects on outcome are essentially the same, and the efficacy of thrombolysis was demonstrated before the newer agents became available.
The other intravenous drugs (urokinase, anisoylated plasminogen streptokinase activator complex, and alteplase [tissue plasminogen activator]), however, are included along with streptokinase in Figure 2, which is designed to show the different years during which a treatment may first appear to be effective when fixed-effects and random-effects models are used. The 60 trials are grouped according to year of publication to make data more legible. In this case heterogeneity in the estimates of the treatment effect postponed statistical significance until a later date when the more conservative method of analysis (that of DerSimonian and Laird7) was used. For all other drugs the difference was no more than one year.
An example of a treatment whose effect on mortality is small enough to require tens of thousands of patients to demonstrate it, beta-blockers for acute myocardial infarction, is presented in Figure 3Figure 3
An Effective Therapy for Acute Myocardial Infarction (Oral or Intravenous Followed by Oral Beta-Blockers) and One with an Unlikely Beneficial Effect (Prophylactic Lidocaine)., along with an example of an unimpressive treatment, prophylactic lidocaine. Again in the case of beta-blockers, two large studies were compatible with the results of the previous small ones.Summaries of the cumulative meta-analyses are presented in Table 1Table 1
Cumulative Meta-Analyses of Treatments of Acute Myocardial Infarction and Secondary Prevention.*. Statistically significant reductions in mortality associated with the treatment of acute myocardial infarction were demonstrated for thrombolytic agents, intravenous nitroglycerin and sodium nitroprusside, antiplatelet agents, anticoagulants, magnesium salts, and beta-blockers. For lidocaine and calcium-channel blockers the differences have not reached statistical significance, and the current difference suggests that these treatments either have no beneficial effect or may be harmful.Statistically significant reductions in long-term mortality that were produced by secondary prevention (as indicated by the movement of the upper confidence interval to a fraction less than 1 ) were demonstrated first for beta-blockers and then for rehabilitation programs, antiplatelet agents, pooled cholesterol-lowering measures (diet, drugs, and ileal-bypass surgery), and oral anticoagulants, in that order. A significant adverse effect was observed when the results of the trials of Class I antiarrhythmic drugs were pooled, and no beneficial effect has been demonstrated for calcium-channel blockers. The benefit of antiplatelet drugs given after myocardial infarction in preventing death was statistically significant after only two studies and 2768 patients in 1976, and after four studies in 1979, but three more studies in 1980 raised the pooled P value to just above 0.05. The reversal to nonsignificance resulted from the inclusion of the Aspirin Myocardial Infarction Study (AMIS), in which the risk factors were significantly maldistributed before the start of therapy.54 The data for aspirin are therefore presented in Table 1 with and without the AMIS results.
The upper limits of the confidence intervals occasionally fluctuate around 1 in our cumulative meta-analyses. In no instance in which one arm of a trial has become statistically significant have we later found a reversal giving the other arm statistical significance.
Table 1 shows the times at which the various independently evaluated treatments became effective at various levels of statistical significance. Certain treatments became significantly effective in a short time or after only a few thousand patients had been randomized. These treatments also had a substantial beneficial clinical effect (a final odds ratio of about 0.80 or less, corresponding to a reduction in mortality of 20 percent or more). Examples are thrombolytic drugs, intravenous vasodilators and magnesium salts, aspirin, and anticoagulants for acute myocardial infarction, and oral beta-blockers and anticoagulants for secondary prevention. For other treatments, the reduction in mortality was smaller, and it did not become statistically significant until tens of thousands of patients had been randomized (e.g., beta-blockers for the treatment of acute myocardial infarction and antiplatelet agents and various approaches to lowering the serum cholesterol for secondary prevention). In the case of prophylactic lidocaine for acute disease and calcium-channel blockers for both treatment and secondary prevention, the odds ratio for mortality was consistently above 1, suggesting a possible harmful effect, but the width of the 95 percent confidence interval prevented the exclusion of a possible beneficial effect (which is likely to be small and of little relevance if it exists at all). Finally, in the case of Class I antiarrhythmic agents for secondary prevention, statistically significant evidence of harm does exist.
Discussion
Issues Raised by Cumulative Meta-Analyses
The technique of performing a new meta-analysis every time a new trial appears raises a number of methodologic and clinical issues. One involves the applicability of the concept of cumulative meta-analysis to the future monitoring of the clinical-trial literature. Should one adjust the P value for statistical significance when multiple testing of the emerging trials is carried out? This issue was previously discussed55 and is currently the subject of methodologic research. Whether routinely to adjust the P value of meta-analyses for multiple looks, as suggested by Yusuf et al.,56 according to the recommended corrections for multiple looks at evolving data in randomized control trials57 is a complex issue.
We recognize that different analysts may use different protocols and therefore include somewhat different research papers, and perhaps different end points and different numerical results, and that these differences can make it difficult to determine when a cumulative meta-analysis becomes positive.
Deciding when to stop ongoing trials or to adopt or reject an investigated treatment is a multifaceted clinical and social problem that cumulative meta-analyses may simplify by supplying important data. Variations in the quality of the individual studies and potential distortions due to publication bias58 59 60 are important factors to be kept in mind when evaluating cumulative meta-analyses.
When does the possibility of publication bias or variation in protocols mean that the results of pooled small trials must be confirmed by very large trials? Experience with the trials of streptokinase and beta-blockers suggests that very large trials confirm the results of the numerous small trials that are reported earlier. It is clear that subgroup responses are more readily determined in big trials, but this deficiency of small trials could be remedied if investigators planning future trials thought in terms of how their data might usefully be combined with those of other studies. Against the need for replication to learn more about subgroups must be weighed the propriety of assigning patients to a control group instead of giving them a treatment shown to be effective by the meta-analysis of a number of small trials.
Another issue in all meta-analyses is the quality and reliability of the original trials. We have included all studies in which patients were assigned to their treatments at random. We would like to go further and adjust the contribution of a given study according to its technical quality.61 However, we have not been able to relate a quantitative estimate of the quality of a study to the size of the observed difference between treatments in a large data base of randomized, controlled trials.62
Implications for the Treatment of Acute Myocardial Infarction
Our meta-analyses suggest that six of the eight individual treatments for reducing mortality due to acute myocardial infarction are highly effective. Similarly, five of the seven methods of preventing or postponing death after discharge are highly effective. There is evidence that these 11 effective agents are not being recommended as often as they might be.5 Perhaps physicians would use these agents more often if they had access to cumulative meta-analyses of the published trials. We recognize, however, that the statistical significance of the accumulated results of randomized, controlled trials is not the only determinant of changes in prescribing by physicians; many other factors may be important in the decision-making process.
In our analyses we have not included data on side effects of the various treatments for several reasons: the difference in total mortality serves as a common measure of all fatal adverse events; the data on side effects in the original publications vary enormously in frequency and quality, especially for the acute phase of infarction; in secondary-prevention studies, quality of life is of real importance, but only recently have original studies paid attention to it. One important complication affecting the quality of life, stroke, was mentioned in only 45 of the 60 trials of thrombolytic agents. The pooled rates of stroke (which could not be separated into thrombotic and hemorrhagic) were 0.7 percent in the control group and 0.8 percent in the treatment group (odds ratio, 1.05; 95 percent confidence interval, 0.85 to 1.30). In ISIS-228 there was a slight increase in the rate of hemorrhagic stroke that was statistically significant. Thus, there may be a slight increase in the rate of hemorrhagic stroke, but that possibility must be weighed against a much greater reduction in the death rate.
Future Applications of Cumulative Meta-Analysis
Our data suggest the desirability of making the results of cumulative meta-analyses available on a regular basis to physicians in every field in which clinical trials are carried out. A prototype of updated but not cumulative meta-analyses is available to obstetricians and perinatologists. The Oxford Database of Perinatal Trials is now in its fourth year of electronic publication.63 The lesson to be learned from our investigation of treatments for myocardial infarction is that trials are often part of a continuum, and those that have gone before must be considered when new ones are planned. To achieve reliable conclusions in the midst of a continuum one needs an efficient way to keep track of available trials. The large task of digesting the ever-expanding literature on clinical trials and disseminating information can be simplified with cumulative meta-analysis.
Supported by grants (PORT-1-PO1-HS 06341–02 and RO1 HS-05936) from the Agency for Health Care Policy and Research, U.S. Public Health Service, Department of Health and Human Services.
Source Information
From the Department of Veterans Affairs Medical Center (J.L., J.J.-S., T.C.C.); the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital (E.M.A.); the Technology Assessment Group, Department of Health Policy and Management, Harvard School of Public Health (T.C.C., B.K., F.M.); the Center for Cardiovascular Health Services Research, New England Medical Center and Tufts University School of Medicine (J.L.); and Harvard Medical School (E.M.A., F.M.) — all in Boston. Address reprint requests to Dr. Chalmers at the Technology Assessment Group, Harvard School of Public Health, 677 Huntington Ave., Boston, MA 02115.
- References
References
1
Yusuf
CrossRef | Web of Science | Medline2
Sacks
Full Text | Web of Science | Medline3
L'Abbé
Web of Science | Medline4
Thacker
CrossRef | Web of Science | Medline5
Antman
CrossRef | Web of Science | Medline6
Mantel
Web of Science | Medline7
DerSimonian
CrossRef | Medline8
Berlin
CrossRef | Web of Science | Medline9
Collins
Full Text | Web of Science | Medline10
Robins
Web of Science | Medline11
Lau 12
Yusuf
CrossRef | Web of Science | Medline13
Stampfer
Full Text | Web of Science | Medline14
Furberg
CrossRef | Web of Science | Medline15
Marder
CrossRef | Web of Science | Medline16
Yusuf
Web of Science | Medline17
Patel
CrossRef | Web of Science | Medline18
Chalmers
CrossRef | Web of Science | Medline19
Topol
Medline20
Naylor
CrossRef | Web of Science | Medline21
Held
CrossRef | Web of Science | Medline22
Honan
CrossRef | Web of Science | Medline23
Yusuf
CrossRef | Web of Science | Medline24
Long-term and short-term beta-blockade after myocardial infarction . Lancet 1982;1:1159–61.
Web of Science | Medline25
Yusuf S. The use of beta-blockers in the acute phase of myocardial infarction. In: Califf RM, Wagner GS, eds. Acute coronary care 1986. Boston: Martinus Nijhoff, 1985:73–88.
26
Chalmers
CrossRef | Web of Science | Medline27
Chalmers
Full Text | Web of Science | Medline28
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
Web of Science | Medline29
MacMahon S, Yusuf S. Effects of lidocaine on ventricular fibrillation, asystole, and early death in patients with suspected acute myocardial infarction. In: Califf RM, Wagner GS, eds. Acute coronary care 1987. Boston: Martinus Nijhoff, 1987:51–60.
30
MacMahon
CrossRef | Web of Science | Medline31
Hine
CrossRef | Web of Science | Medline32
Held
CrossRef | Web of Science | Medline33
Teo
CrossRef | Web of Science | Medline34
Baber
CrossRef | Web of Science | Medline35
Lewis
Web of Science | Medline36
Lewis 37
May
CrossRef | Web of Science | Medline38
Baber
Web of Science39
Furberg
Web of Science40
Loeliger
Medline41
Leizorovicz
CrossRef | Web of Science | Medline42
Kaplan
CrossRef | Web of Science | Medline43
Aspirin after myocardial infarction . Lancet 1980;1:1172–3.
Web of Science | Medline44
Canner
Medline45
Canner
CrossRef | Web of Science | Medline46
Antiplatelet Trialists' Collaboration
CrossRef | Web of Science47
Erkelens
CrossRef | Web of Science | Medline48
Holme
CrossRef | Web of Science | Medline49
Rossouw
Full Text | Web of Science | Medline50
O'Connor
CrossRef | Web of Science | Medline51
Oldridge
CrossRef | Web of Science | Medline52
Hine
CrossRef | Web of Science | Medline53
Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISST)
Web of Science | Medline54
The Aspirin Myocardial Infarction Study Research Group
Web of Science55
Chalmers
CrossRef | Web of Science | Medline56
Yusuf
CrossRef | Web of Science | Medline57
Armitage
CrossRef | Web of Science | Medline58
Rosenthal
CrossRef | Web of Science59
Dickersin
CrossRef | Medline60
Begg
CrossRef | Web of Science61
Detsky
CrossRef | Web of Science62
Emerson
CrossRef | Medline63
Chalmers I, ed. Oxford database of perinatal trials. Version 1.2. Disk issue 6. Oxford, England: Oxford University Press, August 1991.
- Citing Articles (244)
Citing Articles
1
C. E. Adams. (2012) Not At Issue. Schizophrenia Bulletin
CrossRef2
Xue Qin, Qiliu Peng, Zhiyu Zeng, Zhiping Chen, Liwen Lin, Yan Deng, Xiamei Huang, Juanjuan Xu, Huiling Wu, Shan Huang, Shan Li, Jinmin Zhao. (2012) Interleukin-1A −889C/T polymorphism and risk of Alzheimer’s disease: a meta-analysis based on 32 case–control studies. Journal of Neurology
CrossRef3
Eric Benoit, Thomas F. O'Donnell, Georgios D. Kitsios, Mark D. Iafrati. (2011) Improved amputation-free survival in unreconstructable critical limb ischemia and its implications for clinical trial design and quality measurement. Journal of Vascular Surgery
CrossRef4
Kalliopi P. Spyridopoulou, Niki L. Dimou, Stavros J. Hamodrakas, Pantelis G. Bagos. (2011) Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity. Pharmacogenetics and Genomics1
CrossRef5
Elias Zintzaras, Chrysoula Doxani, Dimitrios Ziogas, Theodoros Mprotsis, Paraskevi Rodopoulou, Theofilos Karachalios. (2011) Bone mineral density and genetic markers involved in three connected pathways (focal adhesion, actin cytoskeleton regulation and cell cycle): the CUMAGAS-BMD information system. Biomarkers1-11
CrossRef6
Alexander Tsertsvadze, Margaret Maglione, Roger Chou, Chantelle Garritty, Craig Coleman, Linda Lux, Eric Bass, Howard Balshem, David Moher. (2011) Updating comparative effectiveness reviews: Current efforts in AHRQ's Effective Health Care Program. Journal of Clinical Epidemiology 64:11, 1208-1215
CrossRef7
Elias Zintzaras, Chrysoula Doxani, Paraskevi Rodopoulou, Georgios Bakalos, Dimitris C. Ziogas, Panayiotis Ziakas, Michael Voulgarelis. (2011) Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: A synthesis of genetic association studies. Cancer Epidemiology
CrossRef8
Ingrid Mühlhauser, Matthias Lenz, Gabriele Meyer. (2011) Entwicklung, Bewertung und Synthese von komplexen Interventionen – eine methodische Herausforderung. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
CrossRef9
David Moher, Sally Hopewell, Kenneth F. Schulz, Victor Montori, Peter C. Gøtzsche, P.J. Devereaux, Diana Elbourne, Matthias Egger, Douglas G. Altman. (2011) CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. International Journal of Surgery
CrossRef10
Sofie Kuppens, Mieke Heyvaert, Wim Noortgate, Patrick Onghena. (2011) Sequential meta-analysis of single-case experimental data. Behavior Research Methods 43:3, 720-729
CrossRef11
C. E. Adams. (2011) Cochrane schizophrenia reviews influence on policy and practice: an earthquake zone. Epidemiology and Psychiatric Sciences 20:03, 215-217
CrossRef12
G. K. Nikolopoulos, A. Masgala, C. Tsiara, O. K. Limitsiou, A. C. Karnaouri, N. L. Dimou, P. G. Bagos. (2011) Cytokine gene polymorphisms in multiple sclerosis: a meta-analysis of 45 studies including 7379 cases and 8131 controls. European Journal of Neurology 18:7, 944-951
CrossRef13
Mauricio F. Farez, Jorge Correale. (2011) Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. Journal of Neurology 258:7, 1197-1206
CrossRef14
Steven A. Vasilev. 2011. Evidence-Based Medicine and Decision Support. , 11-41.
CrossRef15
Vincent de Jonge, Jerome Sint Nicolaas, Monique E. van Leerdam, Ernst J. Kuipers. (2011) Overview of the quality assurance movement in health care. Best Practice & Research Clinical Gastroenterology 25:3, 337-347
CrossRef16
Lijuan Yang, Xianghai Zhou, Yingying Luo, Xiuqin Sun, Yong Tang, Wulan Guo, Xueyao Han, Linong Ji. (2011) Association between KCNJ11 gene polymorphisms and risk of type 2 diabetes mellitus in East Asian populations: a meta-analysis in 42,573 individuals. Molecular Biology Reports
CrossRef17
L. Björck, S. Capewell, K. Bennett, G. Lappas, A. Rosengren. (2011) Increasing evidence-based treatments to reduce coronary heart disease mortality in Sweden: quantifying the potential gains. Journal of Internal Medicine 269:4, 452-467
CrossRef18
David J. Maron, William E. Boden, William S. Weintraub, Karen J. Calfas, Robert A. O’Rourke. (2011) Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?. Current Treatment Options in Cardiovascular Medicine 13:1, 16-25
CrossRef19
Elias Zintzaras. (2011) Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease?. Inflammatory Bowel Diseasesn/a-n/a
CrossRef20
P. Cuijpers, T. Donker, A. van Straten, J. Li, G. Andersson. (2010) Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychological Medicine 40:12, 1943-1957
CrossRef21
Emily S Sena, Catherine L Briscoe, David W Howells, Geoffrey A Donnan, Peter A G Sandercock, Malcolm R Macleod. (2010) Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. Journal of Cerebral Blood Flow & Metabolism 30:12, 1905-1913
CrossRef22
Jerome P. Kassirer, John B. Wong. (2010) Comparative Effectiveness Research and the Psychology of Medical Practice. PharmacoEconomics 28:10, 899-903
CrossRef23
J. Brok, L.-L. Gluud, C. Gluud. (2010) Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C - an updated Cochrane review. Alimentary Pharmacology & Therapeutics 32:7, 840-850
CrossRef24
Jessica Gurevitch, Kerrie Mengersen. (2010) A statistical view of synthesizing patterns of species richness along productivity gradients: devils, forests, and trees. Ecology 91:9, 2553-2560
CrossRef25
D Moher. (2010) CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (Chinese version). Journal of Chinese Integrative Medicine701-741
CrossRef26
David Moher, Sally Hopewell, Kenneth F. Schulz, Victor Montori, Peter C. Gøtzsche, P.J. Devereaux, Diana Elbourne, Matthias Egger, Douglas G. Altman. (2010) CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology 63:8, e1-e37
CrossRef27
Elena Kulinskaya, Julia Koricheva. (2010) Use of quality control charts for detection of outliers and temporal trends in cumulative meta-analysis. Research Synthesis Methods 1:3-4, 297-307
CrossRef28
Jennifer Evans. (2010) Evidence-Based Reviews and Meta-Analysis. American Journal of Ophthalmology 149:5, 701-703
CrossRef29
Joseph C. Cappelleri, John P. A. Ioannidis, Joseph Lau. 2010. Meta-Analysis of Therapeutic Trials. , 768-779.
CrossRef30
D. L. Schriger, D. G. Altman, J. A. Vetter, T. Heafner, D. Moher. (2010) Forest plots in reports of systematic reviews: a cross-sectional study reviewing current practice. International Journal of Epidemiology 39:2, 421-429
CrossRef31
M. Bigby, H. C. Williams. 2010. Evidence-Based Dermatology. , 1-23.
CrossRef32
Niki L. Dimou, Georgios K. Nikolopoulos, Stavros J. Hamodrakas, Pantelis G. Bagos. (2010) Fc γ receptor polymorphisms and their association with periodontal disease: a meta-analysis. Journal of Clinical Periodontology 37:3, 255-265
CrossRef33
David J. Maron, William E. Boden, Robert A. O'Rourke, Pamela M. Hartigan, Karen J. Calfas, G.B. John Mancini, John A. Spertus, Marcin Dada, William J. Kostuk, Merril Knudtson, Crystal L. Harris, Steven P. Sedlis, Robert G. Zoble, Lawrence M. Title, Gilbert Gosselin, Shah Nawaz, Gerald T. Gau, Alvin S. Blaustein, Eric R. Bates, Leslee J. Shaw, Daniel S. Berman, Bernard R. Chaitman, William S. Weintraub, Koon K. Teo. (2010) Intensive Multifactorial Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology 55:13, 1348-1358
CrossRef34
SUETONIA C PALMER, SANKAR D NAVANEETHAN, GIOVANNI FM STRIPPOLI. (2010) How to read a nephrology systematic review. Nephrology 15:2, 158-164
CrossRef35
Anastasios Ioannidis, Eleni Ikonomi, Niki L. Dimou, Lelouda Douma, Pantelis G. Bagos. (2010) Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: A Mendelian randomization meta-analysis. Molecular Genetics and Metabolism 99:2, 174-183
CrossRef36
Elias Zintzaras, Georgios D. Kitsios, Afroditi A. Papathanasiou, Spiros Konitsiotis, Michael Miligkos, Paraskevi Rodopoulou, George M. Hadjigeorgiou. (2010) Randomized trials of dopamine agonists in restless legs syndrome: A systematic review, quality assessment, and meta-analysis. Clinical Therapeutics 32:2, 221-237
CrossRef37
Elias Zintzaras. (2010) Genetic variants of homocysteine/folate metabolism pathway and risk of inflammatory bowel disease: a synopsis and meta-analysis of genetic association studies. Biomarkers 15:1, 69-79
CrossRef38
Jian-Bo Zhou, Jin-Kui Yang, Jing-Kai Lu, Yan-Hua An. (2010) Angiotensin-converting enzyme gene polymorphism is associated with type 2 diabetes: a meta-analysis. Molecular Biology Reports 37:1, 67-73
CrossRef39
Judith Anzures-Cabrera, Julian P. T. Higgins. (2010) Graphical displays for meta-analysis: An overview with suggestions for practice. Research Synthesis Methods 1:1, 66-80
CrossRef40
Elias Zintzaras. (2009) Glutathione S-Transferase M1 and T1 Genes and Susceptibility to Chronic Myeloid Leukemia: A Meta-Analysis. Genetic Testing and Molecular Biomarkers 13:6, 791-797
CrossRef41
Hirofumi Nakaoka, Ituro Inoue. (2009) Meta-analysis of genetic association studies: methodologies, between-study heterogeneity and winner's curse. Journal of Human Genetics 54:11, 615-623
CrossRef42
Pantelis G. Bagos, Georgios K. Nikolopoulos. (2009) Generalized least squares for assessing trends in cumulative meta-analysis with applications in genetic epidemiology. Journal of Clinical Epidemiology 62:10, 1037-1044
CrossRef43
W. L. Baker, C. Michael White, J. C. Cappelleri, J. Kluger, C. I. Coleman, . (2009) Understanding heterogeneity in meta-analysis: the role of meta-regression. International Journal of Clinical Practice 63:10, 1426-1434
CrossRef44
Elias Zintzaras, Afroditi A. Papathanasiou, Ioannis Stefanidis. (2009) Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: A HuGE review and meta-analysis. Genetics in Medicine 11:10, 695-706
CrossRef45
Klaus E Meyer, Evis Sinani. (2009) When and where does foreign direct investment generate positive spillovers? A meta-analysis. Journal of International Business Studies 40:7, 1075-1094
CrossRef46
E. Zintzaras. (2009) Inhibin alpha gene and susceptibility to premature ovarian failure: a data synthesis. Molecular Human Reproduction 15:9, 551-555
CrossRef47
Y.W. Yang, C.L. Tsai, C.Y. Lu. (2009) Exclusive breastfeeding and incident atopic dermatitis in childhood: a systematic review and meta-analysis of prospective cohort studies. British Journal of Dermatology 161:2, 373-383
CrossRef48
Elias Zintzaras, Dimitrios C Ziogas, Georgios D Kitsios, Afroditi A Papathanasiou, Joseph Lau, Gowri Raman. (2009) MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics 10:8, 1285-1294
CrossRef49
E. Zintzaras, N. Zdoukopoulos. (2009) A Field Synopsis and Meta-Analysis of Genetic Association Studies in Peripheral Arterial Disease: The CUMAGAS-PAD Database. American Journal of Epidemiology 170:1, 1-11
CrossRef50
George Dranitsaris, Peter Selby, Juan Carlos Negrete. (2009) Meta-Analyses of Placebo-Controlled Trials of Acamprosate for the Treatment of Alcohol Dependence. Journal of Addiction Medicine 3:2, 74-82
CrossRef51
P. G. Bagos. (2009) Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome. Molecular Human Reproduction 15:1, 19-26
CrossRef52
Robert M. Califf. 2009. Clinical Trials. , 13-37.
CrossRef53
E. Zintzaras, P. Rodopoulou, N. Sakellaridis. (2008) Variants of the Arachidonate 5-Lipoxygenase-Activating Protein (ALOX5AP) Gene and Risk of Stroke: A HuGE Gene-Disease Association Review and Meta-Analysis. American Journal of Epidemiology 169:5, 523-532
CrossRef54
Niteesh K. Choudhry, Soko Setoguchi, Raisa Levin, Wolfgang C. Winkelmayer, William H. Shrank. (2008) Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiology and Drug Safety 17:12, 1189-1196
CrossRef55
Yijian Huang, Rebecca Zhang, Steven D Culler, Nancy G Kutner. (2008) Costs and effectiveness of cardiac rehabilitation for dialysis patients following coronary bypass. Kidney International 74:8, 1079-1084
CrossRef56
Ralf Bender, Catey Bunce, Mike Clarke, Simon Gates, Stefan Lange, Nathan L. Pace, Kristian Thorlund. (2008) Attention should be given to multiplicity issues in systematic reviews. Journal of Clinical Epidemiology 61:9, 857-865
CrossRef57
S. Mastenbroek, P. Scriven, M. Twisk, S. Viville, F. Van der Veen, S. Repping. (2008) What next for preimplantation genetic screening? More randomized controlled trials needed?. Human Reproduction 23:12, 2626-2628
CrossRef58
Elias Zintzaras, Joseph Lau. (2008) Synthesis of genetic association studies for pertinent gene–disease associations requires appropriate methodological and statistical approaches. Journal of Clinical Epidemiology 61:7, 634-645
CrossRef59
Niteesh K. Choudhry, Troyen Brennan, Michele Toscano, Claire Spettell, Robert J. Glynn, Mark Rubino, Sebastian Schneeweiss, Alan M. Brookhart, Joaquim Fernandes, Susan Mathew, Blake Christiansen, Elliott M. Antman, Jerry Avorn, William H. Shrank. (2008) Rationale and design of the Post-MI FREEE trial: A randomized evaluation of first-dollar drug coverage for post–myocardial infarction secondary preventive therapies. American Heart Journal 156:1, 31-36
CrossRef60
Pride Chigwedere, George R. Seage, Tun-Hou Lee, M. Essex. (2008) Efficacy of Antiretroviral Drugs in Reducing Mother-to-Child Transmission of HIV in Africa: A Meta-Analysis of Published Clinical Trials. AIDS Research and Human Retroviruses 24:6, 827-837
CrossRef61
Marcel Zwahlen, Andrew Renehan, Matthias Egger. (2008) Meta-analysis in medical research: Potentials and limitations. Urologic Oncology: Seminars and Original Investigations 26:3, 320-329
CrossRef62
Hannah R. Rothstein. (2008) Publication bias as a threat to the validity of meta-analytic results. Journal of Experimental Criminology 4:1, 61-81
CrossRef63
Laurent Fauchier, Bertrand Pierre, Axel de Labriolle, Caroline Grimard, Noura Zannad, Dominique Babuty. (2008) Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation. Journal of the American College of Cardiology 51:8, 828-835
CrossRef64
David Moher, Alexander Tsertsvadze, Andrea Tricco, Martin Eccles, Jeremy Grimshaw, Margaret Sampson, Nick Barrowman, David Moher. 2008. When and how to update systematic reviews. .
CrossRef65
Alvaro Alonso, Joseph Lau, Bertrand L Jaber, Bertrand L Jaber. 2008. Biocompatible hemodialysis membranes for acute renal failure. .
CrossRef66
Scott E. Maxwell, Ken Kelley, Joseph R. Rausch. (2008) Sample Size Planning for Statistical Power and Accuracy in Parameter Estimation. Annual Review of Psychology 59:1, 537-563
CrossRef67
Elias Zintzaras, Joseph Lau. (2008) Trends in meta-analysis of genetic association studies. Journal of Human Genetics 53:1, 1-9
CrossRef68
Michael H. Bennett, Robert J. Turner, DipDHM, Jan P. Lehm, Herbert B. Newton. 2008. Evidence and Hyperbaric Oxygen Therapy. , 451-510.
CrossRef69
John W. Finney. (2008) Regression to the mean in substance use disorder treatment research. Addiction 103:1, 42-52
CrossRef70
Alia I. Sheikh, Sylvia A. Marotta. (2008) Best Practices for Counseling in Cardiac Rehabilitation Settings. Journal of Counseling & Development 86:1, 111-119
CrossRef71
Kunihiro Iwata, Makoto Kubota, Katsuhiko Ogasawara. (2008) Comparsion with myocardial perfusion MRI and myocardial perfusion SPECT in the diagnostic performance of coronary artery disease: A meta-analysis. Japanese Journal of Radiological Technology 64:2, 251-258
CrossRef72
David Moher, Alexander Tsertsvadze, Andrea C. Tricco, Martin Eccles, Jeremy Grimshaw, Margaret Sampson, Nick Barrowman. (2007) A systematic review identified few methods and strategies describing when and how to update systematic reviews. Journal of Clinical Epidemiology 60:11, 1095.e1-1095.e11
CrossRef73
Robert P Dellavalle, Scott R Freeman, Hywel C Williams. (2007) Clinical Evidence Epistemology. Journal of Investigative Dermatology 127:11, 2668-2669
CrossRef74
Elias Zintzaras, Katrin Uhlig, George N. Koukoulis, Afroditi A. Papathanasiou, Ioannis Stefanidis. (2007) Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis. Journal of Human Genetics 52:11, 881-890
CrossRef75
Elias Zintzaras. (2007) Maternal gene polymorphisms involved in folate metabolism and risk of Down syndrome offspring: a meta-analysis. Journal of Human Genetics 52:11, 943-953
CrossRef76
Ramya Raghavan, Bruno S. Benzaquen, Lawrence Rudski. (2007) Timing of bypass surgery in stable patients after acute myocardial infarction. Canadian Journal of Cardiology 23:12, 976-982
CrossRef77
Elias Zintzaras, Nikolaos Sakelaridis. (2007) Is 472G/A catechol-O-methyl-transferase gene polymorphism related to panic disorder?. Psychiatric Genetics 17:5, 267-273
CrossRef78
Argirios E Tsantes, Georgios K Nikolopoulos, Pantelis G Bagos, Chrissa G Tsiara, Violetta Kapsimali, Anthi Travlou, Georgios Vaiopoulos. (2007) Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagulation & Fibrinolysis 18:5, 497-504
CrossRef79
Yoshihisa Hirakawa, Yuichiro Masuda, Masafumi Kuzuya, Takaya Kimata, Akihisa Iguchi, Kazumasa Uemura. (2007) Age-related differences in clinical characteristics, early outcomes and cardiac management of acute myocardial infarction in Japan: Lessons from the Tokai Acute Myocardial Infarction Study (TAMIS). Geriatrics & Gerontology International 7:2, 131-136
CrossRef80
Janet A Curran, Jonathan Dartnell, Kirk Magee, Douglas Sinclair, Patrick J McGrath, Janet A Curran. 2007. Organisational and professional interventions to promote the uptake of evidence in emergency care: Effects on professional practice and health outcomes. .
CrossRef81
Elias Zintzaras. (2007) Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis. Psychiatric Genetics 17:2, 69-75
CrossRef82
Brian H. Rowe, Michael D. Brown. (2007) A Primer on the Cochrane Collaboration, Its New Priorities in Out-of-Hospital and Emergency Health, and the Role of Annals of Emergency Medicine. Annals of Emergency Medicine 49:3, 351-354
CrossRef83
Indranil Banerjee, Veena Gupta, Subramaniam Ganesh. (2007) Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: a meta-analysis. Journal of Human Genetics 52:3, 205-219
CrossRef84
(2007) Hamstring tendon autograft better than bone–patellar tendon–bone autograft in ACL reconstruction—a cumulative meta-analysis and clinically relevant sensitivity analysis applied to a previously published analysis. Acta Orthopaedica 78:5, 705-708
CrossRef85
Georgios K. Nikolopoulos, Argirios E. Tsantes, Pantelis G. Bagos, Anthi Travlou, Georgios Vaiopoulos. (2007) Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: A meta-analysis. Thrombosis Research 119:4, 501-510
CrossRef86
Casper W. Bollen, Cuno S. P. M. Uiterwaal, Adrianus J. van Vught, Ingeborg van der Tweel. (2006) Sequential Meta-analysis of Past Clinical Trials to Determine the Use of a New Trial. Epidemiology 17:6, 644-649
CrossRef87
Elias Zintzaras, Theocharis Koufakis, Panayiotis D. Ziakas, Paraskevi Rodopoulou, Stavroula Giannouli, Michael Voulgarelis. (2006) A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia. European Journal of Epidemiology 21:7, 501-510
CrossRef88
Ned S. Abraham. (2006) WILL THE DILEMMA OF EVIDENCE-BASED SURGERY EVER BE RESOLVED?. ANZ Journal of Surgery 76:9, 855-860
CrossRef89
Alex Cahana, Jan Van Zundert, Lucian Macrea, Maarten van Kleef, Menno Sluijter. (2006) Pulsed Radiofrequency: Current Clinical and Biological Literature Available. Pain Medicine 7:5, 411-423
CrossRef90
Elias Zintzaras. (2006) Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: a meta-analysis. Journal of Human Genetics 51:7, 618-624
CrossRef91
Elias Zintzaras. (2006) C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. Psychiatric Genetics 16:3, 105-115
CrossRef92
Marta Thakkar, Michael O'Shea. (2006) The role of neonatal networks. Seminars in Fetal and Neonatal Medicine 11:2, 105-110
CrossRef93
Elias Zintzaras, Ioannis Stefanidis, Mauro Santos, Francesc Vidal. (2006) Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease?. Hepatology 43:2, 352-361
CrossRef94
P. Muellerleile. (2006) Sufficiency and Stability of Evidence for Public Health Interventions Using Cumulative Meta-Analysis. American Journal of Public Health 96:3, 515-522
CrossRef95
Martin Dennis. (2006) Dysphagia in acute stroke: a long-awaited trial. The Lancet Neurology 5:1, 16-17
CrossRef96
Albert Cobos-Carbó. (2005) Ensayos clínicos aleatorizados (CONSORT). Medicina Clínica 125, 21-27
CrossRef97
James P. Rathmell, Jane C. Ballantyne. (2005) Local Anesthetics for the Treatment of Neuropathic Pain: On the Limits of Meta-Analysis. Anesthesia & Analgesia1736-1737
CrossRef98
Elias Zintzaras, Georgios M. Hadjigeorgiou. (2005) The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson’s disease: a meta-analysis. Journal of Human Genetics 50:11, 560-566
CrossRef99
A. Glasmacher, M. von Lilienfeld-Toal, S. Schulte, C. Hahn, I. G. H. Schmidt-Wolf, A. Prentice. (2005) An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clinical Microbiology and Infection 11:s5, 17-23
CrossRef100
Davy C. Cheng, Daniel Bainbridge, Janet E. Martin, Richard J. Novick. (2005) Underreporting of Conversion from Off-pump Coronary Artery Bypass Surgery. Anesthesiology 103:4, 902-903
CrossRef101
Shahzad G. Raja. (2005) Off-pump Coronary Artery Bypass: Randomized Trials, Real-world Experience, Clinical Relevance, and Statistical Significance. Anesthesiology 103:4, 901-902
CrossRef102
Fred G. Barker, Bob S. Carter. (2005) Synthesizing medical evidence: systematic reviews and metaanalyses. Neurosurgical FOCUS 19:4, 1-21
CrossRef103
Roger Chou. (2005) Evidence-Based Medicine and the Challenge of Low Back Pain: Where Are We Now?. Pain Practice 5:3, 153-178
CrossRef104
Simon G. Thompson. 2005. Meta-Analysis of Clinical Trials. .
CrossRef105
Donna F. Stroup, Stephen B. Thacker. 2005. Meta-Analysis in Epidemiology. .
CrossRef106
Jan van Dixhoorn, Adrian White. (2005) Relaxation therapy for rehabilitation and prevention in ischaemic heart disease: a systematic review and meta-analysis. European Journal of Cardiovascular Prevention & Rehabilitation 12:3, 193-202
CrossRef107
John P.A. Ioannidis, Thomas A. Trikalinos. (2005) Early extreme contradictory estimates may appear in published research: The Proteus phenomenon in molecular genetics research and randomized trials. Journal of Clinical Epidemiology 58:6, 543-549
CrossRef108
Elias Zintzaras, Dimitrios Z. Chatzoulis, Costas H. Karabatsas, Ioannis Stefanidis. (2005) The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. Journal of Human Genetics 50:6, 267-275
CrossRef109
Artyom Sedrakyan, Ken O’Byrne. (2005) Reply to the Editor. The Journal of Thoracic and Cardiovascular Surgery 129:5, 1205-1206
CrossRef110
A Alonso, J Lau, BL Jaber, Bertrand Jaber. 2005. Biocompatible hemodialysis membranes for acute renal failure. .
CrossRef111
Kristin O'Neil-Callahan, George Katsimaglis, Micah R. Tepper, Jason Ryan, Carla Mosby, John P.A. Ioannidis, Peter G. Danias. (2005) Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. Journal of the American College of Cardiology 45:3, 336-342
CrossRef112
John Victor Peter, John L. Moran, Jennie Phillips-Hughes. (2005) A metaanalysis of treatment outcomes of early enteral versus early parenteral nutrition in hospitalized patients*. Critical Care Medicine 33:1, 213-220
CrossRef113
Thomas A. Trikalinos, Rachel Churchill, Marica Ferri, Stefan Leucht, Arja Tuunainen, Kristian Wahlbeck, John P.A. Ioannidis. (2004) Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology 57:11, 1124-1130
CrossRef114
Mary Wyatt, Martin R. Underwood, Inger B. Scheel, J David Cassidy, Peter Nagel. (2004) Back Pain and Health Policy Research: The What, Why, How, Who, and When. Spine 29:20, E468-E475
CrossRef115
Adesuwa B. Olomu, Ralph E. Watson, Azfar-e-Alam Siddiqi, Francesca C. Dwamena, Barbara A. McIntosh, Peter Vasilenko, Joel Kupersmith, Margaret M. Holmes-Rovner, . (2004) Changes in Rates of Beta-blocker Use in Community Hospital Patients with Acute Myocardial Infarction. Journal of General Internal Medicine 19:10, 999-1004
CrossRef116
Heli Nykänen, Julia Koricheva. (2004) Damage-induced changes in woody plants and their effects on insect herbivore performance: a meta-analysis. Oikos 104:2, 247-268
CrossRef117
Alvaro Alonso, Joseph Lau, Bertrand L. Jaber, Andrew Weintraub, Mark J. Sarnak. (2004) Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. American Journal of Kidney Diseases 43:1, 1-9
CrossRef118
Charles F. Babbs. (2003) Interposed abdominal compression CPR: a comprehensive evidence based review. Resuscitation 59:1, 71-82
CrossRef119
Ida Sim, Steven R. Cummings. (2003) A New Framework for Describing and Quantifying the Gap Between Proof and Practice. Medical Care 41:8, 874-881
CrossRef120
J.A. Critchley, S. Capewell, B. Unal. (2003) Life-years gained from coronary heart disease mortality reduction in Scotland. Journal of Clinical Epidemiology 56:6, 583-590
CrossRef121
F. Pelagotti, M. Cecchi, A. Messori, . (2003) Use of gabexate mesylate in Italian hospitals: a multicentre observational study. Journal of Clinical Pharmacy and Therapeutics 28:3, 191-196
CrossRef122
Charles F. Babbs. (2003) Simplified meta-analysis of clinical trials in resuscitation. Resuscitation 57:3, 245-255
CrossRef123
MA Papadopoulos. (2003) Meta-analysis in evidence-based orthodontics. Orthodontics & Craniofacial Research 6:2, 112-126
CrossRef124
MA Papadopoulos. (2003) Meta-analysis in evidence-based orthodontics. Orthodontics and Craniofacial Research 6:2, 112-126
CrossRef125
John P.A. Ioannidis. (2003) Genetic associations: false or true?. Trends in Molecular Medicine 9:4, 135-138
CrossRef126
Fotini B Karassa, Thomas A Trikalinos, John PA Ioannidis. (2003) The FcγRIIIA-F158 allele is a risk factor for the development of lupus nephritis: A meta-analysis. Kidney International 63:4, 1475-1482
CrossRef127
John PA Ioannidis, Thomas A Trikalinos, Evangelia E Ntzani, Despina G Contopoulos-Ioannidis. (2003) Genetic associations in large versus small studies: an empirical assessment. The Lancet 361:9357, 567-571
CrossRef128
Randall S Stafford, David C Radley. (2003) The underutilization of cardiacmedications of proven benefit, 1990 to 2002. Journal of the American College of Cardiology 41:1, 56-61
CrossRef129
Robert H. Fletcher. (2002) Evaluation of interventions. Journal of Clinical Epidemiology 55:12, 1183-1190
CrossRef130
Gabriel Thabut, Dominique Thabut, Robert P Myers, Brigitte Bernard-Chabert, Rolana Marrash-Chahla, Hervé Mal, Michel Fournier. (2002) Thrombolytic therapy of pulmonary embolism. Journal of the American College of Cardiology 40:9, 1660-1667
CrossRef131
Hilda Blanco. (2002) The map of science collaboratory. Systems Research and Behavioral Science 19:5, 441-454
CrossRef132
Fred G. Barker. (2002) Efficacy of Prophylactic Antibiotic Therapy in Spinal Surgery: A Meta-analysis. Neurosurgery 51:2, 391-401
CrossRef133
M. Soledad Cepeda, Joseph Lau, Daniel B. Carr. (2002) Defining the Therapeutic Role of Local Anesthetic Sympathetic Blockade in Complex Regional Pain Syndrome: A Narrative and Systematic Review. The Clinical Journal of Pain 18:4, 216-233
CrossRef134
Malcolm Man-Son-Hing, Andreas Laupacis, Keith O'Rourke, Frank J. Molnar, Jeffery Mahon, Karen B. Y. Chan, George Wells. (2002) Determination of the Clinical Importance of Study Results. A Review. Journal of General Internal Medicine 17:6, 469-476
CrossRef135
Ida Sim, Gillian D. Sanders, Kathryn M. McDonald. (2002) Evidence-based Practice for Mere Mortals. The Role of Informatics and Health Services Research. Journal of General Internal Medicine 17:4, 302-308
CrossRef136
John V. Peter, John L. Moran, Jennie Phillips-Hughes, David Warn. (2002) Noninvasive ventilation in acute respiratory failure— A meta-analysis update. Critical Care Medicine 30:3, 555-562
CrossRef137
Timothy W. Smith, John M. Ruiz. (2002) Psychosocial influences on the development and course of coronary heart disease: Current status and implications for research and practice.. Journal of Consulting and Clinical Psychology 70:3, 548-568
CrossRef138
Mahesh KB Parmar, David J Spiegelhalter, Gareth O Griffiths, Douglas G Altman, Robert L Souhami. (2002) Bayesian stopping rules for trials. The Lancet 359:9300, 76-77
CrossRef139
H. Williams. (2001) Dowling Oration 2001Evidence-based dermatology - a bridge too far?. Clinical and Experimental Dermatology 26:8, 714-724
CrossRef140
Charles F. Babbs. (2001) Consensus evidence evaluation in resuscitation research: analysis of Type I and Type II errors. Resuscitation 51:2, 193-205
CrossRef141
R. Gillett. (2001) Meta-analysis and bias in research reviews. Journal of Reproductive and Infant Psychology 19:4, 287-294
CrossRef142
TIMOTHY E. PATERICK, GERALD F. FLETCHER. (2001) Endothelial Function and Cardiovascular Prevention: Role of Blood Lipids, Exercise, and Other Risk Factors. Cardiology in Review 9:5, 282-286
CrossRef143
Jean-Pierre Pignon, Catherine Hill. (2001) Meta-analyses of randomised clinical trials in oncology. The Lancet Oncology 2:8, 475-482
CrossRef144
Rose Wiles, Ann-Louise Kinmonth. (2001) Patients’ understandings of heart attack: implications for prevention of recurrence. Patient Education and Counseling 44:2, 161-169
CrossRef145
J. Jaime Caro, Maribel Salas, Alexandra Ward, Glenwood Goss. (2001) Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 91:12, 2214-2221
CrossRef146
Mark A. Papworth, Derek L. Milne. (2001) Qualitative systematic review: An example from primary prevention in adult mental health. Journal of Community & Applied Social Psychology 11:3, 193-210
CrossRef147
David Massel, Stephen H Little. (2001) Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. Journal of the American College of Cardiology 37:2, 569-578
CrossRef148
Judith Jolliffe, Karen Rees, Rod RS Taylor, David R Thompson, Neil Oldridge, Shah Ebrahim, Judith Jolliffe. 2001. Exercise-based rehabilitation for coronary heart disease. .
CrossRef149
Toshiro TANGO. (2001) Meta-Analysis: Aiming to Integrate the Evidence. Kodo Keiryogaku (The Japanese Journal of Behaviormetrics) 28:2, 56-67
CrossRef150
Teresa C. Prevost, Keith R. Abrams, David R. Jones. (2000) Hierarchical models in generalized synthesis of evidence: an example based on studies of breast cancer screening. Statistics in Medicine 19:24, 3359-3376
CrossRef151
Bruce E. Wampold, Hyunnie Ahn, Dongmin Kim. (2000) Meta-analysis in the social sciences:. Asia Pacific Education Review 1:1, 67-74
CrossRef152
R S Wright, S L Kopecky, G S Reeder. (2000) Update on intravenous fibrinolytic therapy for acute myocardial infarction.. Mayo Clinic Proceedings 75:11, 1185-1191
CrossRef153
John P.A. Ioannidis, Christopher H. Schmid, Joseph Lau. (2000) META-ANALYSIS IN HEMATOLOGY AND ONCOLOGY. Hematology/Oncology Clinics of North America 14:4, 973-991
CrossRef154
Eric A. Engels, Christopher H. Schmid, Norma Terrin, Ingram Olkin, Joseph Lau. (2000) Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Statistics in Medicine 19:13, 1707-1728
CrossRef155
David J. Maron. (2000) Percutaneous coronary intervention versus medical therapy for coronary heart disease. Current Atherosclerosis Reports 2:4, 290-296
CrossRef156
Benjamin Djulbegovic, Lou Morris, Gary H. Lyman. (2000) Evidentiary challenges to evidence-based medicine. Journal of Evaluation in Clinical Practice 6:2, 99-109
CrossRef157
Alan F Schatzberg, Helena C Kraemer. (2000) Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biological Psychiatry 47:8, 736-744
CrossRef158
Barry A. Franklin. (2000) How Much Exercise is Enough for the Coronary Patient?. Preventive Cardiology 3:2, 63-70
CrossRef159
Gerald V. Naccarelli, Deborah L. Wolbrette, Joseph T. Dell'Orfano, Hemantkumar M. Patel, Jerry C. Luck. (2000) Amiodarone: What have we learned from clinical trials?. Clinical Cardiology 23:2, 73-82
CrossRef160
E.John Gallagher. (2000) Clots in the lung. Annals of Emergency Medicine 35:2, 181-187
CrossRef161
Clifford S Goodman, Roy Ahn. (1999) Methodological approaches of health technology assessment. International Journal of Medical Informatics 56:1-3, 97-105
CrossRef162
J. P. A. Ioannidis, J. Lau. (1999) State of the Evidence: Current Status and Prospects of Meta-Analysisin Infectious Diseases. Clinical Infectious Diseases 29:5, 1178-1185
CrossRef163
Ingram Olkin. (1999) Diagnostic statistical procedures in medical meta-analyses. Statistics in Medicine 18:17-18, 2331-2341
CrossRef164
John P.A Ioannidis, Despina G Contopoulos-Ioannidis, Joseph Lau. (1999) Recursive Cumulative Meta-analysis. Journal of Clinical Epidemiology 52:4, 281-291
CrossRef165
Soumerai, Stephen B., Ross-Degnan, Dennis, . (1999) Inadequate Prescription-Drug Coverage for Medicare Enrollees — A Call to Action. New England Journal of Medicine 340:9, 722-728
Full Text166
Calogero Camma, Marco Giunta, Giovanbattista Pinzello, Alberto Morabito, Paolo Verderio, Luigi Pagliaro. (1999) Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. The American Journal of Gastroenterology 94:3, 581-595
CrossRef167
Christopher J. Williams. (1999) Is health economics useful in cancer?. Critical Reviews in Oncology/Hematology 30:1, 25-33
CrossRef168
J. DAVID TALLEY. (1999) Medical Management of Acute Coronary Syndromes. Journal of Interventional Cardiology 12:1, 33-49
CrossRef169
Harold L. Kennedy. (1999) The importance of randomized clinical trials and evidence-based medicine: A clinician's perspective. Clinical Cardiology 22:1, 6-12
CrossRef170
DAMIEN DOWNING. (1999) Is ISIS-4 research misconduct?. Journal of Nutritional and Environmental Medicine 9:1, 5-13
CrossRef171
Maria da Graça Bourquin, Vincent Wietlisbach, Martin Rickenbach, François Perret, Fred Paccaud. (1998) Time Trends in the Treatment of Acute Myocardial Infarction in Switzerland from 1986 to 1993. Journal of Clinical Epidemiology 51:9, 723-732
CrossRef172
GERALD V. NACCARELLLI, DEBORAH L. WOLBRETTE, JOSEPH T. DELL'ORFANO, HEMANTKUMAR M. PATEL, JERRY C. LUCK. (1998) A Decade of Clinical Trial Developments in Postmyocardial Infarction, Congestive Heart Failure, and Sustained Ventricular Tachyarrhythmia Patients: From CAST to AVID and Beyond. Journal of Cardiovascular Electrophysiology 9:8, 864-891
CrossRef173
Attilio Maseri. (1998) Evidence-based medicine: Progress but not a final solution. Clinical Cardiology 21:7, 463-464
CrossRef174
STEPHEN B. THACKER, DONNA F. STROUP, HERBERT B. PETERSON. (1998) Intrapartum Electronic Fetal Monitoring: Data for Clinical Decisions. Clinical Obstetrics and Gynecology 41:2, 362-368
CrossRef175
KAY DICKERSIN, ERIC MANHEIMER. (1998) The Cochrane Collaboration: Evaluation of Health Care and Services Using Systematic Reviews of the Results of Randomized Controlled Trials. Clinical Obstetrics and Gynecology 41:2, 315-331
CrossRef176
STEPHEN B. THACKER, DONNA F. STROUP, HERBERT B. PETERSON. (1998) Meta-Analysis for the Practicing Obstetrician-Gynecologist. Clinical Obstetrics and Gynecology 41:2, 275-281
CrossRef177
Bertram L. Kasiske. (1998) Meta-analysis as a clinical tool in nephrology. Kidney International 53:4, 819-825
CrossRef178
David E. Gutstein, Valentin Fuster. (1998) Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. Clinical Cardiology 21:3, 161-168
CrossRef179
Janice Pogue, Salim Yusuf. (1998) Overcoming the limitations of current meta-analysis of randomised controlled trials. The Lancet 351:9095, 47-52
CrossRef180
David S. Krantz, Nicole R. Lundgren. 1998. Cardiovascular Disorders. , 189-216.
CrossRef181
Dave Davis. (1998) Does CME Work? An Analysis of the Effect of Educational Activities On Physician Performance or Health Care Outcomes. The International Journal of Psychiatry in Medicine 28:1, 21-39
CrossRef182
Michael Borenstein. 1998. The Shift from Significance Testing to Effect Size Estimation. , 313-349.
CrossRef183
S Yusuf. (1997) Meta-analysis of randomized trials: Looking back and looking ahead. Controlled Clinical Trials 18:6, 594-601
CrossRef184
P Nony, M Cucherat, MC Haugh, JP Boissel. (1997) Standardization of terminology in meta-analysis: a proposal for working definitions. Fundamental & Clinical Pharmacology 11:6, 481-493
CrossRef185
John P.A. Ioannidis, Joseph Lau. (1997) The impact of high-risk patients on the results of clinical trials. Journal of Clinical Epidemiology 50:10, 1089-1098
CrossRef186
Sheldon Xiaodong Kong, Stephanie Y. Crawford, Sanjay K. Gandhi, John D. Seeger, Glen T. Schumock, Nancy P. Lam, JoAnn Stubbings, Marieke Dekker Schoen. (1997) Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials. Clinical Therapeutics 19:4, 778-797
CrossRef187
Robert H. Fletcher, Suzanne W. Fletcher. (1997) Evidence-Based Approach to the Medical Literature. Journal of General Internal Medicine 12:s2, 5-14
CrossRef188
Richard Horton. (1997) A manifesto for reading medicine. The Lancet 349:9055, 872-874
CrossRef189
Mangano, Dennis T., Layug, Elizabeth L., Wallace, Arthur, Tateo, Ida, . (1996) Effect of Atenolol on Mortality and Cardiovascular Morbidity after Noncardiac Surgery. New England Journal of Medicine 335:23, 1713-1721
Full Text190
Jeroan J. Allison, Catarina I. Kiefe, Robert M. Centor, J. Brent Box, Robert M. Farmer. (1996) Racial differences in the medical treatment of elderly medicare patients with acute myocardial infarction. Journal of General Internal Medicine 11:12, 736-743
CrossRef191
Wood, Alastair J.J., , Hennekens, Charles H., Albert, Christine M., Godfried, Susan L., Gaziano, J. Michael, Buring, Julie E., . (1996) Adjunctive Drug Therapy of Acute Myocardial Infarction — Evidence from Clinical Trials. New England Journal of Medicine 335:22, 1660-1668
Full Text192
Dave Davis. (1996) Physician education, evidence and the coming of age of CME. Journal of General Internal Medicine 11:11, 705-706
CrossRef193
Randal J. Thomas, Nancy Houston Miller, Cindy Lamendola, Kathy Berra, Bo Hedb??ck, J. Larry Durstine, William Haskell. (1996) National Survey on Gender Differences in Cardiac Rehabilitation Programs: PATIENT CHARACTERISTICS AND ENROLLMENT PATTERNS. Journal of Cardiopulmonary Rehabilitation 16:6, 402-412
CrossRef194
Patrick Vandekerckhove, Richard Lilford, Tasuku Harada, Edward Hughes, Andrew Watson, Patrick Vandekerckhove. 1996. Oil-soluble versus water-soluble media for assessing tubal patency with hysterosalpingography or laparoscopy in subfertile women. .
CrossRef195
C Berkey. (1996) Uncertainty of the time of first significance in random effects cumulative meta-analysis. Controlled Clinical Trials 17:5, 357-371
CrossRef196
Michael G. Gelder. (1996) Which treatments are effective: an epidemiological perspective. Epidemiologia e Psichiatria Sociale 5:02, 108-113
CrossRef197
Stephen B. Thacker, Herbert B. Peterson, Donna F. Stroup. (1996) Metaanalysis for the obstetrician-gynecologist. American Journal of Obstetrics and Gynecology 174:5, 1403-1407
CrossRef198
Jean L. Rouleau, Mario Talajic, Bruce Sussex, Louise Potvin, Wayne Warnica, Richard F. Davies, Martin Gardner, Duncan Stewart, Sylvain Plante, Robert Dupuis, Claude Lauzon, John Ferguson, Etel Mikes, Vidoslav Balnozan, Pierre Savard. (1996) Myocardial infarction patients in the 1990s—their risk factors, stratification and survival in Canada: The Canadian assessment of myocardial infarction (CAMI) study. Journal of the American College of Cardiology 27:5, 1119-1127
CrossRef199
Julia B. Freeman, Susan J. Blalock, Halsted R. Holman, Matthew H. Liang, Robert F. Meenan. (1996) Advances brought by health services research to patients with arthritis: Summary of the workshop on health services research in arthritis: From research to practice. Arthritis Care & Research 9:2, 142-150
CrossRef200
Judith Lumley, Hilda Bastian. (1996) Competing or Complementary?: Ethical Considerations and the Quality of Randomized Trials. International Journal of Technology Assessment in Health Care 12:02, 247
CrossRef201
J Denollet, H Rombouts, T.C Gillebert, D.L Brutsaert, S.U Sys, D.L Brutsaert, N Stroobant. (1996) Personality as independent predictor of long-term mortality in patients with coronary heart disease. The Lancet 347:8999, 417-421
CrossRef202
L. Candelise, C. Roncaglioni, E. Aritzu, A. Ciccone, A. P. Maggioni, . (1996) Thrombolytic therapy. From myocardial to cerebral infarction. The Italian Journal of Neurological Sciences 17:1, 5-21
CrossRef203
D Downing, H M Anthony, S Birtwhistle, K K Eaton, J R Mansfield, J M Meldrum, M J Radcliffe. (1996) Effective Nutritional Medicine: The Application of Nutrition to Major Health Problems: British Society for Allergy and Environmental Medicine with the British Society for Nutritional Medicine. Journal of Nutritional and Environmental Medicine 6:2, 191-232
CrossRef204
W Henderson. (1995) Use of cumulative meta-analysis in the design, monitoring, and final analysis of a clinical trial: A case study. Controlled Clinical Trials 16:5, 331-341
CrossRef205
Joel Tsevat, Daniella Duke, Lee Goldman, Marc A. Pfeffer, Gervasio A. Lamas, Jane R. Soukup, Karen M. Kuntz, Thomas H. Lee. (1995) Cost-effectiveness of captopril therapy after myocardial infarction. Journal of the American College of Cardiology 26:4, 914-919
CrossRef206
Harold L. Kennedy, Robert S. Rosenson. (1995) Physician use of beta-adrenergic blocking therapy: a changing perspective. Journal of the American College of Cardiology 26:2, 547-552
CrossRef207
John C. Sinclair. (1995) Meta-analysis of randomized controlled trials of antenatal corticosteroid for the prevention of respiratory distress syndrome: Discussion. American Journal of Obstetrics and Gynecology 173:1, 335-344
CrossRef208
(1995) A primer on outcomes research for the gastroenterologist: Report of the American gastroenterological association task force on outcomes research. Gastroenterology 109:1, 302-306
CrossRef209
Joseph Lau, Thomas C. Chalmers. (1995) The Rational Use of Therapeutic Drugs in the 21st Century: Important Lessons from Cumulative Meta-analyses of Randomized Control Trials. International Journal of Technology Assessment in Health Care 11:03, 509
CrossRef210
A. Mark Fendrick. (1995) Thrombolytic therapy. Journal of General Internal Medicine 10:6, 351-352
CrossRef211
C. M. Airey, D. R. R. Williams. (1995) Cochrane Collaborative Review Group: Diabetes. Diabetic Medicine 12:5, 375-376
CrossRef212
Luis Alcocer, Germán Novoa, David Sotres. (1995) Meta-analysis of three trials with quinapril in the treatment of mild-to-moderate hypertension in the Mexican population. Clinical Therapeutics 17:3, 552-560
CrossRef213
Brent A. Blumenstein. (1995) Overview analysis issues using combined androgen deprivation overview analysis as an example. Urologic Oncology: Seminars and Original Investigations 1:3, 95-100
CrossRef214
P.-J. Souquet, F. Chauvin, J.P. Boissel, J.P. Bernard. (1995) Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer 12, S147-S154
CrossRef215
J. Villar, G. Carroli, J.M. Belizán. (1995) Predictive ability of meta-analyses of randomised controlled trials. The Lancet 345:8952, 772-776
CrossRef216
A.J. Petros, J.C. Marshall, H.K.F. van Saene. (1995) Should morbidity replace mortality as an endpoint for clinical trials in intensive care?. The Lancet 345:8946, 369-371
CrossRef217
David R. Jones. (1995) Meta-analysis: Weighing the evidence. Statistics in Medicine 14:2, 137-149
CrossRef218
Arild Bjømdal. (1995) Editorial: Evidence based practice. Scandinavian Journal of Primary Health Care 13:1, 1-2
CrossRef219
Les Irwig. (1995) “A statistician looks at met-analysis”: Discussion. Journal of Clinical Epidemiology 48:1, 105-108
CrossRef220
Joseph Lau, Christopher H. Schmid, Thomas C. Chalmers. (1995) Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. Journal of Clinical Epidemiology 48:1, 45-57
CrossRef221
Stephen F. Jencks. (1994) HCFA's health care quality improvement program and the cooperative cardiovascular project. The Annals of Thoracic Surgery 58:6, 1858-1862
CrossRef222
Deborah J. Cook, Gordon H. Guyatt. (1994) Dissent The professional meta-analyst: An evolutionary advantage. Journal of Clinical Epidemiology 47:12, 1327-1329
CrossRef223
Ayanian, John Z.Hauptman, Paul J.Guadagnoli, EdwardAntman, Elliott MPashos, Chris L.McNeil, Barbara J.. (1994) Knowledge and Practices of Generalist and Specialist Physicians Regarding Drug Therapy for Acute Myocardial Infarction. New England Journal of Medicine 331:17, 1136-1142
Full Text224
SHEILA A. ROBERTS, MARLOS A. VIANA, JOSE NAZARI, JERRY L. BAUMAN. (1994) Invasive and Noninvasive Methods to Predict the Long-Term Efficacy of Amiodarone: A Compilation of Clinical Observations Using Meta-Analysis. Pacing and Clinical Electrophysiology 17:10, 1590-1602
CrossRef225
Howard E. Rockette, David Gur, William L. Campbell, F. Leland Thaete. (1994) Use of meta-analysis in the evaluation of imaging systems. Academic Radiology 1:1, 63-69
CrossRef226
Lewis H. Kuller. (1994) Future in lipid and lipoprotein research: from preventing clinical disease to preventing elevated risk factors. Atherosclerosis 108, S143-S156
CrossRef227
M. Baum, J. Houghton, K. Abrams. (1994) Early stopping rules - clinical perspectives and ethical considerations. Statistics in Medicine 13:13-14, 1459-1469
CrossRef228
Monty M. Bodenheimer, Deborah Sauer, Babar Shareef, Mary W. Brown, Joseph L. Fleiss, Arthur J. Moss. (1994) Relation between myocardial infarct location and stroke. Journal of the American College of Cardiology 24:1, 61-66
CrossRef229
Carin M. Olson. (1994) Understanding and Evaluating a Meta-analysis. Academic Emergency Medicine 1:4, 392-398
CrossRef230
K.L. Woods, S. Fletcher. (1994) Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). The Lancet 343:8901, 816-819
CrossRef231
Chris L. Pashos, Sharon-Lise T. Normand, Jeffrey B. Garfinkle, Joseph P. Newhouse, Arnold M. Epstein, Barbara J. McNeil. (1994) Trends in the use of drag therapies in patients with acute myocardial infarction: 1988 to 1992. Journal of the American College of Cardiology 23:5, 1023-1030
CrossRef232
Michael L. Fisher, Stephen S. Gottlieb, Gary D. Plotnick, Nancy L. Greenberg, Richard D. Patten, Susan K. Bennett, Bruce P. Hamilton. (1994) Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. Journal of the American College of Cardiology 23:4, 943-950
CrossRef233
Mohammad F. Huque, Satya D. Dubey. (1994) A meta-analysis methodology for utilizing study-level covariate information from clinical trials. Communications in Statistics - Theory and Methods 23:2, 377-394
CrossRef234
Donald E. Moore, Joseph S. Green, Stephen J. Jay, James C. Leist, Frances M. Maitland. (1994) Creating a new paradigm for CME: Seizing opportunities within the health care revolution. Journal of Continuing Education in the Health Professions 14:1, 4-31
CrossRef235
R. BRIAN HAYNES. (1993) Some Problems in Applying Evidence in Clinical Practice. Annals of the New York Academy of Sciences 703:1 Doing More Go, 210-225
CrossRef236
THOMAS C. CHALMERS, JOSEPH LAU. (1993) Randomized Control Trials and Meta-Analyses in Gastroenterology: Major Achievements and Future Potential. Annals of the New York Academy of Sciences 703:1 Doing More Go, 96-106
CrossRef237
A. V. Pollock. (1993) Surgical evaluation at the crossroads. British Journal of Surgery 80:8, 964-966
CrossRef238
J.P. Bernard, P.J. Souquet, J.P. Boissel, F. Chauvin, R. Cellerino, D. Tumarello, Y. Cormier, P.A. Ganz, S. Kaasa, J.L. Pater, E. Quoix, E. Rapp, J. Williams, B.L. Woods. (1993) Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. The Lancet 342:8862, 19-21
CrossRef239
C.M. Viscoli, M.S. Lachs, R.I. Horwitz. (1993) Bladder cancer and coffee drinking: a summary of case-control research. The Lancet 341:8858, 1432-1437
CrossRef240
(1993) ACE Inhibitors after Myocardial Infarction. New England Journal of Medicine 328:13, 966-969
Full Text241
M. von Planta, D. Chamberlain. (1992) Drug treatment of arrhythmias during cardiopulmonary resuscitation. Resuscitation 24:3, 227-232
CrossRef242
(1992) Redundant Publication?. New England Journal of Medicine 327:18, 1316-1316
Full Text243
(1992) Hirudins: return of the leech?. The Lancet 340:8819, 579-580
CrossRef244
Kassirer, Jerome P., . (1992) Clinical Trials and Meta-Analysis. New England Journal of Medicine 327:4, 273-274
Full Text
- Letters
